Two-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age.

What Was Tested

This phase 4 clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The primary study objective is to assess the long-term effect of Omnitrope treatment on the development of diabetes in short children born SGA.

Why It Was Studied

Here the researchers report data from patients who have completed 2 years' treatment.

Who Took Part

By PubMed's age tags, the people studied were young children and children, both men and women.

Eligibility criteria included prepubertal children born SGA with growth disturbances defined as current height standard deviation score (HSDS) <-2.5 and parental adjusted SDS <-1; birth weight and/or length <-2 SDS; and failure of catch-up growth [height velocity (HV) SDS <0 during the last year] by 4 years of age or later.

How the Study Was Run

The researchers set it up as an open-label and multicenter study.

Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the participants and staff both knew the treatment.

Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Body Height, Glucose Tolerance Test, Growth Disorders, Human Growth Hormone, Infant, Small for Gestational Age and Recombinant Proteins.

The authors tagged it with the keywords Endocrinology, Omnitrope, Recombinant human growth hormone and Somatropin.

What This Means in Plain Language

The paper is an open-label and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Advances in therapy), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.